Cargando…
Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development
Cardiotoxicity is among the top drug safety concerns, and is of specific interest in tuberculosis, where this is a known or potential adverse event of current and emerging treatment regimens. As there is a need for a tool, beyond the QT interval, to quantify cardiotoxicity early in drug development,...
Autores principales: | Polak, Sebastian, Romero, Klaus, Berg, Alexander, Patel, Nikunjkumar, Jamei, Masoud, Hermann, David, Hanna, Debra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953981/ https://www.ncbi.nlm.nih.gov/pubmed/29520534 http://dx.doi.org/10.1007/s10928-018-9580-2 |
Ejemplares similares
-
Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
por: Humphries, Helen, et al.
Publicado: (2021) -
Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability
por: Chetty, Manoranjenni, et al.
Publicado: (2014) -
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development
por: Gumbo, Tawanda, et al.
Publicado: (2023) -
Multi‐phase multi‐layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin
por: Patel, Nikunjkumar, et al.
Publicado: (2022) -
Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study
por: Fijorek, Kamil, et al.
Publicado: (2013)